Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15101577 | 0.86 | HRH3 (0.65) | KDM4EHRH3ALDH1A1 | |
| SCHEMBL12449641 | 0.83 | KDM4E (0.54) | KDM4EHRH3LMNASMN1; SMN2GAA | |
| SCHEMBL13102 | 0.83 | KDM4E (0.54) | KDM4EHRH3LMNASMN1; SMN2GAA | |
| SCHEMBL2114689 | 0.82 | KDM4E (0.49) | KDM4EHRH3ALDH1A1 | |
| SCHEMBL738472 | 0.82 | KDM4E (0.49) | KDM4EHRH3ALDH1A1 | |
| SCHEMBL12449637 | 0.82 | KDM4E (0.51) | KDM4EHRH3ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12449635 | 0.82 | KDM4E (0.51) | KDM4EHRH3ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL13003 | 0.82 | KDM4E (0.51) | KDM4EHRH3ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL17277355 | 0.81 | KDM4E (0.39) | KDM4EHRH3ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12062331 | 0.80 | KDM4E (0.38) | KDM4EHRH3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488525-B1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS INC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-9193731-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | KDM4E 4344/4885HRH3 3537/4885ALDH1A1 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.